SGTX NASDAQ
Sigilon Therapeutics, Inc.
1W: +0.0%
1M: +5.0%
3M: +200.4%
1Y: +152.2%
$22.47
Last traded 2023-08-18 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$13M
+34.8% ▲
4Y CAGR: +29.3%
Gross Profit
$13M
+34.8% ▲
4Y CAGR: +29.3%
Operating Income
-$44M
+42.3% ▲
Net Income
-$43M
+44.5% ▲
EPS (Diluted)
$-1.34
+95.8% ▲
EBITDA
-$39M
+45.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $5M | $14M | $13M | $10M | $13M |
| YoY Growth | +0.0% | +205.3% | -5.5% | -28.2% | +34.8% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $5M | $14M | $13M | $10M | $13M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D Expenses | $21M | $48M | $53M | $65M | $38M |
| SG&A Expenses | $7M | $10M | $13M | $20M | $19M |
| Operating Expenses | $28M | $58M | $66M | $85M | $57M |
| Operating Income | -$23M | -$44M | -$53M | -$76M | -$44M |
| Operating Margin | -497.6% | -311.7% | -393.6% | -788.0% | -337.3% |
| Interest Expense | $289K | $650K | $1M | $2M | $2M |
| Income Before Tax | -$23M | -$44M | -$55M | -$77M | -$44M |
| Tax Expense | $0 | $644K | $259K | $925K | -$105K |
| Net Income | -$23M | -$45M | -$55M | -$78M | -$43M |
| Net Margin | -490.9% | -314.9% | -410.3% | -815.0% | -335.7% |
| EPS (Diluted) | $-18.85 | $-27.53 | $-22.67 | $-31.92 | $-1.34 |
| EBITDA | -$22M | -$42M | -$53M | -$75M | -$39M |
| Shares Outstanding | 1M | 2M | 2M | 2M | 32M |